Faeth Therapeutics holder reports 2% ownership stake

Faeth Therapeutics, Inc. received an amended Schedule 13G/A from Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai reporting their ownership of Faeth common stock.

Rhea-AI Filing Summary

Faeth Therapeutics, Inc. received an amended Schedule 13G/A from Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai reporting their ownership of Faeth common stock. As of June 30, 2026, the filers may be deemed to beneficially own 515,335 shares of common stock, representing 2.0% of the company’s outstanding shares. All reported shares are held directly by Trails Edge Biotechnology Master Fund, with Trails Edge Capital as investment manager and Mr. Yehudai exercising voting and investment discretion. The ownership percentages are based on 25,778,754 Faeth common shares outstanding as of June 15, 2026. The filing also notes that the filers hold 5 percent or less of this class of securities.

Key Figures

Shares beneficially owned: 515,335 shares Ownership percentage: 2.0% Shares outstanding: 25,778,754 shares +2 more

5 metrics

Shares beneficially owned 515,335 shares Common Stock beneficially owned by each filer as of June 30, 2026

Ownership percentage 2.0% Percent of Faeth Therapeutics common stock class held by the filers

Shares outstanding 25,778,754 shares Faeth Therapeutics common shares outstanding as of June 15, 2026

Sole voting power 515,335 shares Shares over which the filers report sole power to vote

Sole dispositive power 515,335 shares Shares over which the filers report sole power to dispose

Key Terms

beneficially own, sole dispositive power, sole voting power, Schedule 13G/A, +1 more

5 terms

beneficially own financial

"each Filer may be deemed to beneficially own an aggregate of 515,335 shares"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

sole dispositive power financial

"Sole Dispositive Power 515,335.00 8 | Shared Dispositive Power 0.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

sole voting power financial

"Sole Voting Power 515,335.00 6 | Shared Voting Power 0.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Schedule 13G/A regulatory

"This report on /A (as amended, this "") is being filed"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Joint Filing Agreement regulatory

"Exhibit 1- Joint Filing Agreement, dated as of February 25, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake in Faeth Therapeutics (FTH) does Trails Edge report in this Schedule 13G/A amendment?

The filers report beneficial ownership of 515,335 shares of Faeth Therapeutics common stock, representing 2.0% of the outstanding shares as of June 30, 2026, all held directly by Trails Edge Biotechnology Master Fund.

Who are the reporting persons in the Faeth Therapeutics (FTH) Schedule 13G/A?

The reporting persons are Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai. Trails Edge Capital manages the fund, and Mr. Yehudai, as Chief Investment Officer, exercises voting and investment discretion over the reported shares.

What percentage of Faeth Therapeutics (FTH) does Trails Edge beneficially own?

The filers state they beneficially own 2.0% of Faeth Therapeutics’ common stock. This percentage is calculated using 25,778,754 common shares outstanding as of June 15, 2026, as reported by the company in a prior Form 8-K.

How many Faeth Therapeutics (FTH) shares are outstanding for this ownership calculation?

The ownership calculation uses 25,778,754 Faeth Therapeutics common shares outstanding as of June 15, 2026. This figure comes from the company’s Form 8-K and serves as the basis for the reported 2.0% ownership stake.

Do the Trails Edge filers have sole or shared voting power over Faeth Therapeutics (FTH) shares?

The filers report 515,335 shares with sole voting power and sole dispositive power, and 0 shares with shared voting or shared dispositive power. All shares are held directly by Trails Edge Biotechnology Master Fund.

Does this Faeth Therapeutics (FTH) Schedule 13G/A indicate ownership above or below 5%?

The filing indicates beneficial ownership of 5 percent or less of the common stock class. Specifically, the reported stake is 2.0% of Faeth Therapeutics’ outstanding common shares as of the referenced dates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 04:21 PM Accepted by SEC EDGAR 08/14/2026 - 04:15 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Faeth Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

81728A207

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 81728A207

1

Names of Reporting Persons

Trails Edge Capital Partners, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 515,335.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 515,335.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

515,335.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.0 %

12

Type of Reporting Person (See Instructions)

IA, PN

Comment for Type of Reporting Person: See Item 4 for additional information.

SCHEDULE 13G

CUSIP Number(s): 81728A207

1

Names of Reporting Persons

Trails Edge Biotechnology Master Fund, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 515,335.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 515,335.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

515,335.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.0 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: See Item 4 for additional information.

SCHEDULE 13G

CUSIP Number(s): 81728A207

1

Names of Reporting Persons

Ortav Yehudai

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 515,335.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 515,335.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

515,335.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.0 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: See Item 4 for additional information.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Faeth Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 701 Tillery Street #12 #1010, Austin, TX 78702
Item 2.
(a)	Name of person filing: This report on Schedule 13G/A (as amended, this "Schedule 13G") is being filed by Trails Edge Capital Partners, LP, a Delaware limited partnership ("Trails Edge Capital"), Trails Edge Biotechnology Master Fund, LP, a Cayman Islands limited partnership ("Trails Edge Biotechnology"), and Ortav Yehudai ("Mr. Yehudai"). Trails Edge Capital is the investment manager to Trails Edge Biotechnology, and Mr. Yehudai is the Chief Investment Officer of Trails Edge Capital. Each of Trails Edge Capital, Trails Edge Biotechnology and Mr. Yehudai are referred to individually as a "Filer" and collectively as the "Filers".
(b)	Address or principal business office or, if none, residence: The address for each Filer is 3455 Peachtree Road NE, 5th Floor, Atlanta, GA 30326.
(c)	Citizenship: See Item 4 of the cover page of each Filer.
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 81728A207
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: As of June 30, 2026 (the "Event Date"), each Filer may be deemed to beneficially own an aggregate of 515,335 shares (the "Shares") of Common Stock, par value $0.0001 per share (the "Common Stock"), of Faeth Therapeutics, Inc. (the "Issuer"). The 515,335 Shares reported as beneficially owned on this Schedule 13G by each Filer consists of 515,335 Shares held directly by Trails Edge Biotechnology. As a result, Trails Edge Biotechnology beneficially owns 2.0% of the outstanding Shares of the Issuer as of the Event Date. Trails Edge Capital, as the investment manager to Trails Edge Biotechnology, may be deemed to beneficially own these securities. Mr. Yehudai, as the Chief Investment Officer of Trails Edge Capital, exercises voting and investment discretion with respect to these securities and as such may be deemed to beneficially own 2.0% of the outstanding Shares of the Issuer as of the Event Date. Ownership percentages are based on 25,778,754 shares of Common Stock issued and outstanding as of June 15, 2026, as reported by the Issuer in its Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 18, 2026.
(b)	Percent of class: 2.0%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 515,335.00
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 515,335.00
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Trails Edge Capital Partners, LP

Signature:	/s/ Trails Edge Capital Partners, LLC, GP of Trails Edge Capital Partners, LP /s/ Ortav Yehudai
Name/Title:	Ortav Yehudai / Chief Investment Officer of Trails Edge Capital Partners, LLC
Date:	08/14/2026

Trails Edge Biotechnology Master Fund, LP

Signature:	/s/ Trails Edge GP, LLC, GP of Trails Edge Biotechnology Fund GP, LP, GP of Trails Edge Biotechnology Master Fund, LP /s/ Ortav Yehudai
Name/Title:	Ortav Yehudai / Chief Investment Officer of Trails Edge GP, LLC
Date:	08/14/2026

Ortav Yehudai

Signature:	/s/ Ortav Yehudai
Name/Title:	Ortav Yehudai / Individual
Date:	08/14/2026

Exhibit Information

Exhibit 1- Joint Filing Agreement, dated as of February 25, 2026, by and between Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP and Ortav Yehudai (incorporated by reference to Exhibit 1 to the Schedule 13G filed with the Securities and Exchange Commission on February 25, 2026).